d31b7542-ab53-4c4f-b070-0c50bb195d1c
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- INTERFERON_ALPHA_RESPONSE+0.500
- MYC_TARGETS_V1+0.500
- OXIDATIVE_PHOSPHORYLATION+0.500
- G2M_CHECKPOINT+0.400
- MTORC1_SIGNALING+0.400
- MYC_TARGETS_V2+0.400
- PANCREAS_BETA_CELLS+0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.400
- INTERFERON_GAMMA_RESPONSE+0.300
Top 10 suppressed
- TGF_BETA_SIGNALING-0.400
- APICAL_SURFACE-0.300
- ESTROGEN_RESPONSE_EARLY-0.300
- ESTROGEN_RESPONSE_LATE-0.300
- HEDGEHOG_SIGNALING-0.300
- KRAS_SIGNALING_DN-0.300
- P53_PATHWAY-0.300
- TNFA_SIGNALING_VIA_NFKB-0.300
- WNT_BETA_CATENIN_SIGNALING-0.300
- APICAL_JUNCTION-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518360 | — | E | 0.839 |
| 2 | SRR27320678 | — | — | 0.833 |
| 3 | SRR11296765 | — | — | 0.811 |
| 4 | TCGA-BH-A18U-01A-21R-A12D-07 | — | C | 0.807 |
| 5 | SRR17866821 | — | — | 0.796 |
| 6 | MNG767 | — | — | 0.796 |
| 7 | TCGA-05-4415-01A-22R-1858-07 | — | cohortA4 | 0.792 |
| 8 | SRR10841996 | — | — | 0.786 |
| 9 | TCGA-38-4625-01A-01R-1206-07 | — | cohortA1 | 0.781 |
| 10 | 34c0a7a8-8ce8-4a2a-9bce-939eb2f6f1d9 | — | — | 0.781 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.400 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.100 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |